Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025• APEX trial enrollment in AdvSM patients complete; top-line results ...

Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before ...

Avelumab plus axitinib was effective and safe in real-world advanced kidney cancer, with outcomes matching clinical trials, ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Avelumab in combination with axitinib was found effective and safe as frontline treatment for advanced RCC in real-world ...

The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...

In a real-world analysis of patients with advanced RCC, the combination of first-line Bavencio and Inlyta was effective and ...

Chen, D. and Li, L. (2025) Huge Pelvic GIST Got Good Control after Resistance to Tyrosine Kinase Inhibitors by SIB-IMRT: A ...

为解决胶质瘤治疗难题，作者 [第一作者单位] 研究人员开展肿瘤微环境基质细胞对胶质瘤影响的研究。结果发现基质细胞在胶质瘤发展中作用关键且有对应靶向药物。推荐阅读，助您了解胶质瘤治疗新方向。 胶质瘤（glioma），这个名字听起来或许有些陌生，但它却是成年人中枢神经系统中最常见的原发性恶性肿瘤。它就像隐藏在大脑里的 ...

(Nasdaq: EXEL) today announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating CABOMETYX® (cabozantinib) in combination with Opdivo® (nivolumab) versus sunitinib for ...

Background: Thioredoxin reductase (Trx) has been implicated in activation of hypoxia-inducible factor-1α, which is overexpressed in > 85% of renal cell carcinomas (RCCs). We evaluated the safety ...

A targeted therapy is one that has been developed to affect a specific target, such as an enzyme or receptor. Targeted therapies can either block or increase the function of their target in order ...